Document ID: chunk:federal_register_of_legislation:F2025C00039:reg:73433
Version: federal_register_of_legislation:F2025C00039
Segment Type: reg
Provision Reference: reg 73433
Character Range: 20761–22251

73433              Next generation sequencing (NGS) test for neurotrophic receptor tyrosine kinase (NTRK1, NTRK2, NTRK3) fusions by RNA or DNA in tumour tissue from a patient with locally advanced or metastatic solid tumour, if:                                                                                                                                                                                                                                                                                                                                                                                                                                          1,000.00

                       (a) the tumour is at risk of being caused by an NTRK gene fusion as determined by either:
                          (i) occurring in a child less than 18 years of age; or
                          (ii) being mammary analogue secretory carcinoma of the salivary gland; or
                          (iii) being secretory breast carcinoma;

                       (b) the test is requested by a specialist or consultant physician to determine if requirements relating to NTRK gene fusion status for access to a tropomyosin receptor kinase (Trk) inhibitor under the Pharmaceutical Benefits Scheme are fulfilled

                   This item cannot be claimed if item 73430 has been claimed for the same patient during the same cancer diagnosis

                   Applicable only once per cancer diagnosis